Bristol Myers Squibb ended its partnership with Cellares, a chimeric antigen receptor T-cell manufacturing and workflow partner. Cellares said a “large pharmaceutical customer” decided to terminate the deal based on manufacturing requirements tied to making commercial Breyanzi (lisocabtagene maraleucel), with Cellares disputing BMS’s characterization that the Cell Shuttle system could not meet the requirements. The termination triggers restructuring at Cellares and raises near-term operational questions for CAR-T manufacturing vendors as customers align production platforms with quality, release, and throughput expectations for commercial supply. For the cell therapy supply chain, the incident highlights how quickly CDMO relationships can shift when technical specifications for commercial manufacturing tighten.